newsfilter
← Latest News
GlobeNewswire·

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus